Devonian Health Group Past Earnings Performance
Past criteria checks 0/6
Devonian Health Group's earnings have been declining at an average annual rate of -6%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been declining at an average rate of 12.6% per year.
Key information
-6.0%
Earnings growth rate
11.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | -12.6% |
| Return on equity | -32.5% |
| Net Margin | -85.1% |
| Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
Recent updates
Is Devonian Health Group (CVE:GSD) A Risky Investment?
Mar 20
Is Devonian Health Group (CVE:GSD) Using Debt In A Risky Way?
Dec 01Is Devonian Health Group (CVE:GSD) Weighed On By Its Debt Load?
Aug 18Does Devonian Health Group (CVE:GSD) Have A Healthy Balance Sheet?
Apr 24Does Devonian Health Group's (CVE:GSD) CEO Salary Compare Well With Industry Peers?
Mar 02Revenue & Expenses BreakdownBeta
How Devonian Health Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 5 | -4 | 4 | 1 |
| 31 Oct 23 | 3 | -4 | 4 | 1 |
| 31 Jul 23 | 2 | -5 | 4 | 1 |
| 30 Apr 23 | 2 | -5 | 3 | 1 |
| 31 Jan 23 | 2 | -4 | 3 | 1 |
| 31 Oct 22 | 2 | -4 | 3 | 1 |
| 31 Jul 22 | 2 | -3 | 3 | 1 |
| 30 Apr 22 | 2 | -4 | 2 | 1 |
| 31 Jan 22 | 2 | -4 | 2 | 0 |
| 31 Oct 21 | 1 | -3 | 2 | 0 |
| 31 Jul 21 | 1 | -3 | 1 | 1 |
| 30 Apr 21 | 1 | -4 | 2 | 1 |
| 31 Jan 21 | 2 | -4 | 2 | 1 |
| 31 Oct 20 | 2 | -4 | 2 | 1 |
| 31 Jul 20 | 2 | -4 | 2 | 2 |
| 30 Apr 20 | 0 | -4 | 0 | 2 |
| 31 Jan 20 | 0 | -4 | 1 | 2 |
| 31 Oct 19 | 3 | -3 | 2 | 1 |
| 31 Jul 19 | 4 | -3 | 3 | 1 |
| 30 Apr 19 | 7 | -3 | 7 | 1 |
| 31 Jan 19 | 8 | -3 | 6 | 1 |
| 31 Oct 18 | 5 | -3 | 4 | 1 |
| 31 Jul 18 | 3 | -3 | 4 | 1 |
| 30 Apr 18 | 2 | -5 | 2 | 1 |
| 31 Jan 18 | 0 | -5 | 2 | 1 |
| 31 Oct 17 | 0 | -5 | 2 | 1 |
| 31 Jul 17 | 0 | -4 | 2 | 0 |
| 30 Apr 17 | 0 | -2 | 1 | 0 |
| 31 Jan 17 | 0 | -2 | 1 | 0 |
| 31 Oct 16 | 0 | -2 | 1 | 1 |
| 31 Jul 16 | 0 | -2 | 1 | 1 |
Quality Earnings: GSD is currently unprofitable.
Growing Profit Margin: GSD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GSD is unprofitable, and losses have increased over the past 5 years at a rate of 6% per year.
Accelerating Growth: Unable to compare GSD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GSD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: GSD has a negative Return on Equity (-32.53%), as it is currently unprofitable.